Conference Call with Indoco Remedies Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Indoco Remedies announced Q1FY23 Result : During the first quarter of FY 2022-23, revenues of Indoco Remedies grew by 3.6% at Rs. 394.9 crores, as against Rs.381.2 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.1% at Rs. 71.3 crores, compared to 22.8% at Rs. 86.8 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 9.7% at Rs. 38.5 crores, compared to 10.4% at Rs. 39.6 crores, same quarter last year. Commenting on the first quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “After a turbulent India Business performance of last year with highs & lows of Covid, I am happy to report that we have a steady performance in the Domestic Business and an excellent growth in the International Business” Result PDF